NCT06052852 2025-11-17Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesBolt Biotherapeutics, Inc.Phase 1 Terminated17 enrolled
NCT03792841 2025-10-16Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPCAmgenPhase 1 Terminated212 enrolled
NCT05704985 2025-05-29Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ TumorsDEKA BiosciencesPhase 1 Active not recruiting39 enrolled